Strand has developed the first platform for the creation of programmable, long-acting mRNA therapeutics capable of delivering multi-functional treatments for deadly diseases, with an initial aim of ...

BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient ...

For many, mRNA-based medicines are synonymous with COVID-19 vaccines, but vaccination is just the tip of the iceberg for the technology. Strand Therapeutics is one of the companies looking below the ...

-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...

An impressive array of Big Pharma backers lined up to ensure Strand Therapeutics has the funding needed to take its mRNA-based solid tumor drug further into the clinic. New Strand supporters that ...

As the first vaccines for Covid-19 rolled out at the end of 2020, messenger RNA catapulted into public awareness. Now, a few years later, interest in mRNA has exploded. Clinical trials are underway ...